Logo

OpiCalc

FavoritesSpecialtiesDrugsGuidelinesMost Used

All Specialties

OpiCalc Logo
FavoritesSpecialtiesDrugsGuidelinesMost Used
FavesSpecsDrugsGuidesTop
ALBI Grade (Liver)ASTCT GradingATA Thyroid RiskBCLC 2022 Staging (HCC)BSA (Mosteller)CLL-IPICML ELTS ScoreCNS-IPICTCAE v5.0Calvert FormulaDIPSS-Plus (Myelofibrosis)Deauville ScoreEAU NMIBC RiskECOG Performance StatusELN 2022 Risk (AML)ELN CML MilestonesFIGO 2021 (Ovarian)FIGO 2023 (Endometrial)FLIPI-2Fleischner 2017 GuidelinesFong Clinical Risk ScoreHCT-CI (Sorror Score)HPV/p16 OropharynxIGCCCG Risk (Testicular)IMDC (Heng) CriteriaIMWG Myeloma FrailtyIPSS-M (Molecular MDS)ISUP Grade GroupsKarnofsky Status (KPS)Khorana ScoreLugano ClassificationLung-RADS v2022MIPI-b (Biological)MRD Assessment FrameworkMSI/MMR InterpretationMayo 20/2/20 (SMM)NCCN Prostate RiskNCCN-IPI (DLBCL)NSCLC GPAOncotype DX RecurrenceOpioid EquianalgesicPD-L1 TPS InterpretationPERCIST 2.0PREDICT v3.0Platinum-Free IntervalR2-ISS (Revised 2)RANO 2.0RCB (Residual Cancer Burden)RECIST 1.1ROMA ScoreSAVER ScoreSINS ScoreSLiM-CRAB CriteriaSedlis/Peters CriteriaTNM 8th (Colorectal)TNM 8th Ed (Prognostic)TNM 9th (Nasopharynx)TNM 9th Ed (NSCLC)TNM 9th Ed (SCLC)Tyrer-Cuzick (IBIS v8)WHO 2021 CNS Class.WHO 2022 / ICC 2022 AMLZ0011 EligibilityiRECISTiwCLL 2018 ResponsemRECIST (HCC)mRENAL ScoremrTRG (Rectal MRI)
OpiCalc Logo

OpiCalc

Easy, fast, and private medical tools for clinicians. Always free.

No Login Required
Ready for the Bedside

Resources

About UsEditorial PolicyMedical DisclaimerPrivacy PolicyTerms of UseCookie Policy

Support

Contact Us

Clinical Notice:OpiCalc is not a substitute for professional clinical judgment. Always verify dosages and guidelines.

OpiCalc © 2018-2026

•

All Rights Reserved

Recent Journal Updates

Cancer MedicineJun 8, 2026
Retrospective Analysis of HER2 Testing, Treatment Patterns, and Clinical Outcomes in Patients With Locally Advanced or Metastatic NSCLC With HER2 Mutations in France

Clinical Context

We think this might be relevant to the clinical guidance for TNM 9th Ed (SCLC).

DiabetologiaJun 6, 2026
Plasma small RNA profiling reveals a three-miRNA signature associated with early beta cell dysfunction across glucose tolerance stages

Clinical Context

We think this has broad domain relevance to TNM 9th Ed (SCLC).

DiabetologiaJun 5, 2026
Early glycaemic exposure and cancer risk in people with newly diagnosed type 2 diabetes

Clinical Context

We think this has broad domain relevance to TNM 9th Ed (SCLC).

TNM 9th Ed (SCLC)

TNM 9THSCLC Staging Framework (VALSG/AJCC)

Clinical Extent

Staging Nuance

While the AJCC TNM 9th Edition provides detailed anatomic staging, the VALSG system (Limited vs Extensive) remains the primary driver of treatment decisions in clinical practice for SCLC.

Therapeutic Strategy

Limited Stage

Management Path

Limited-stage SCLC. Curative-intent concurrent chemoradiotherapy is the standard of care.

Guidelines & Evidence

Verified

Last Review: 2026

When to Use

Clinical Use

All patients with biopsy-confirmed Small Cell Lung Cancer.
Initial staging to determine if the patient is a candidate for curative-intent concurrent chemoradiation.
Helps identify the extremely rare subset (Stage I-II, T1-2 N0) that may benefit from surgical resection.

Related Scores in Practice

In clinical practice, this assessment is frequently evaluated alongside other validated measures. Depending on the patient's presentation and specific diagnostic requirements, you may also need to utilize the TNM 9th Ed (NSCLC) or the PD-L1 TPS Interpretation to formulate a comprehensive care plan.

Last Comprehensive Review: 2026

Related Oncology Tools

TNM 9th Ed
PD-L1 TPS Interpretation
Calvert Formula
IMWG Myeloma Frailty
EAU NMIBC Risk
TNM 8th
mrTRG
TNM 9th
PREDICT v3.0
SINS Score
Oncology CalculatorsInternal Medicine CalculatorsEmergency Medicine Calculators
Have feedback about this calculator?Let us know.